Cogent Biosciences, Inc. (COGT) intrinsic value & 10-year financials
Cogent Biosciences, Inc. (COGT) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $29.52
- Market cap
- $3.8B
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -2.0%
- ROIC (10-yr avg)
- 636.7%
- Free cash flow (FY2025)
- -$266.0M
COGT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$328.9M | -$2.16 | -$266.0M | — | -90.6% |
| FY2024 | — | -$255.9M | -$1.94 | -$208.4M | — | -129.2% |
| FY2023 | — | -$192.4M | -$2.42 | -$156.4M | — | -108.1% |
| FY2022 | — | -$140.2M | -$2.39 | -$125.5M | — | -216.7% |
| FY2021 | — | -$72.3M | -$1.87 | -$60.5M | — | 1599.5% |
| FY2020 | $7.9M | -$74.8M | — | — | -1044.3% | 2663.6% |
| FY2019 | $22.5M | -$31.8M | — | -$41.5M | -143.0% | 2548.7% |
| FY2018 | $9.7M | -$34.5M | — | -$33.0M | -369.9% | -606.5% |
| FY2017 | $8.4M | -$25.5M | — | -$26.7M | -312.8% | 69.3% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cogent Biosciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cogent Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -22.1% ROIC.
Cogent Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Cogent Biosciences, Inc. is modeled at -2.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-8.42 per share.